NCT04390334View on ClinicalTrials.gov

A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 13, 2020

Primary Completion Date

June 26, 2020

Study Completion Date

June 26, 2020

Conditions
Healthy
Interventions
DRUG

Daridorexant

Daridorexant will be administered orally as 1 film-coated tablet of 50 mg strength to be taken in the morning under fasted conditions.

DRUG

Famotidine

Famotidine will be administered orally as 1 film-coated tablet of 40 mg strength to be taken in the morning under fasted conditions.

DRUG

Efavirenz

Efavirenz will be administered orally as 1 film-coated tablet of 600 mg strength o.d. in the evening.

Trial Locations (1)

68167

CRS Clinical Research Services Mannheim GmbH, Mannheim

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT04390334 - A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant. | Biotech Hunter | Biotech Hunter